MRI, near-infrared spectral tomography combination increases specificity in breast cancer imaging

Magnetic resonance imaging and near-infrared spectral tomography is feasible and more accurate than MRI alone
Magnetic resonance imaging and near-infrared spectral tomography is feasible and more accurate than MRI alone

By combining two imaging modalities, investigators demonstrated that a dual breast examination using magnetic resonance imaging (MRI) and near-infrared spectral tomography (NIRST) is feasible and more accurate than MRI alone. Their study was published in Clinical Cancer Research (2015; doi:10.1158/1078-0432.CCR-14-2546).

“The research is exciting because it shows for the first time, in the largest clinical study to date of the combined MRI+NIRST imaging approach, that improvement in the specificity of breast MRI is possible by adding NIRST to the imaging procedure,” explained study leader Keith Paulsen, PhD, of the Norris Cotton Cancer Center at Dartmouth College in Hanover, New Hampshire.

“Other reports suggested that such improvement was possible, but they included small numbers of clinical exams that were not sufficiently large enough to show a statistically significant improvement.”

Breast MRI is the most sensitive imaging technique for cancer surveillance and is recommended for screening in women with elevated risk of breast cancer. Unfortunately, breast MRI generates many false positives, showing regions of the breast that are enhanced under imaging technology but are not malignant.

Better imaging could provide additional information for clinicians and potentially reduce the number of MRI-guided biopsies.

Paulsen's study investigated whether the addition of molecular imaging (NIRST) at the time of MRI would improve the diagnostic accuracy of breast MRI alone by contributing functional information about regions of suspicion in the breast identified by the MRI and helping to categorize the regions as malignant or benign.

The study showed that data from the combined imaging procedure improved specificity from 67% for MRI alone, to 89% when tissue optical index (TOI) from NIRST imaging was added. The sensitivity did not decrease, remaining high at 95%, and the area under the curve (AUC) increased to 0.95 from 0.86 for MRI alone.

“Working with our Chinese colleagues at Xijing Hospital, we found that a combined MRI+NIRST breast exam is feasible as a clinical breast imaging procedure, and that the data from the combined imaging modalities is diagnostically more accurate,” said Paulsen.

RELATED: No association between opioids, breast cancer recurrence

“In particular, this combination improves on what is reported by breast MRI alone. With additional technical improvements related to exam set-up and delivery, the approach is ready for evaluation in larger clinical studies, including multicenter trials.”

Looking forward, Paulsen plans to refine the technology to improve its clinical acceptance, making it easier to use and seamless in the standard clinical workflow of breast MRI, as well as increasing the areas of breast coverage with the NIRST sensors.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs